Nutriband (NASDAQ:NTRB – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Institutional and Insider Ownership
19.7% of Nutriband shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Nutriband and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutriband | -430.35% | -109.07% | -95.54% |
| Evolus | -10.85% | N/A | -13.00% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus price target of $14.50, indicating a potential upside of 81.93%. Given Evolus’ stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Nutriband.
Risk and Volatility
Nutriband has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
Valuation and Earnings
This table compares Nutriband and Evolus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutriband | $2.04 million | 47.69 | -$8.23 million | ($0.53) | -15.09 |
| Evolus | $297.18 million | 1.77 | -$51.64 million | ($0.52) | -15.33 |
Nutriband has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.
Summary
Evolus beats Nutriband on 9 of the 14 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
